sb 203580 has been researched along with clofibric acid in 1 studies
Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (clofibric acid) | Trials (clofibric acid) | Recent Studies (post-2010) (clofibric acid) |
---|---|---|---|---|---|
3,489 | 4 | 1,137 | 1,429 | 103 | 120 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Kim, YK; Kwon, CH; Yoon, CS | 1 |
1 other study(ies) available for sb 203580 and clofibric acid
Article | Year |
---|---|
Ciglitazone induces caspase-independent apoptosis via p38-dependent AIF nuclear translocation in renal epithelial cells.
Topics: Active Transport, Cell Nucleus; Animals; Apoptosis; Apoptosis Inducing Factor; Blotting, Western; Cell Line; Cell Nucleus; Cell Survival; Chromans; Clofibric Acid; Dose-Response Relationship, Drug; Epithelial Cells; Fibric Acids; Flow Cytometry; Fluorescent Antibody Technique; G1 Phase; Imidazoles; Kidney Tubules; Membrane Potential, Mitochondrial; Opossums; p38 Mitogen-Activated Protein Kinases; PPAR gamma; Pyridines; Thiazolidinediones; Troglitazone | 2008 |